Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in REPL — Replimune Group, Inc.

CIK 1423053 MIAMI, FL
Back to REPL Full portfolio

Position in REPL

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$3,050,276
+$1,511,028 QoQ
Shares Held
398,729
+151.8% QoQ
Ownership
0.475%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
24 quarters on record
Voting authority Sole 100% Shared 0% None 0%

Common Shares in REPL Over Time

Shares Held

Position Value (USD)

Derivatives in REPL

reported options exposure · as of Mar 31, 2026
CallValue
$1,889,550
CallShares
247,000
PutValue
$1,362,465
PutShares
178,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,784,241,435 across 374 Biotechnology names. REPL ranks #167 (0.1% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in REPL

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $1,889,550 247,000
2026-03-31 $1,362,465 178,100
2026-03-31 $3,050,276 398,729
2025-12-31 $1,539,248 158,359
2025-12-31 $2,431,944 250,200
2025-12-31 $987,552 101,600
2025-09-30 $503,771 120,232
2025-09-30 $1,068,450 255,000
2025-09-30 $1,633,262 389,800
2025-06-30 $2,577,733 277,474
2025-06-30 $1,412,080 152,000
2025-06-30 $1,501,264 161,600
2025-03-31 $610,350 62,600
2025-03-31 $221,861 22,755
2025-03-31 $94,575 9,700
2024-12-31 $96,880 8,000
2024-12-31 $41,174 3,400
2024-12-31 $1,651,367 136,364
2024-09-30 $1,488,137 135,779
2024-09-30 $111,792 10,200
2024-09-30 $139,192 12,700
2024-06-30 $36,900 4,100
2024-06-30 $1,933,974 214,886
2024-06-30 $82,800 9,200
2024-03-31 $227,126 27,800
2024-03-31 $148,694 18,200
2024-03-31 $550,984 67,440
2023-12-31 $148,368 17,600
2023-12-31 $1,749,536 207,537
2023-12-31 $612,018 72,600
2023-09-30 $1,786,284 104,400
2023-09-30 $20,481,268 1,197,035
2023-09-30 $1,904,343 111,300
2023-06-30 $26,380,659 1,136,118
2023-06-30 $297,216 12,800
2023-06-30 $631,584 27,200
2023-03-31 $121,854 6,900
2023-03-31 $19,689,345 1,114,912
2023-03-31 $49,448 2,800
2022-12-31 $27,200 1,000
2022-12-31 $15,122,547 555,976
2022-12-31 $2,325,600 85,500
2022-09-30 $11,156,816 646,023
2022-09-30 $1,471,404 85,200
2022-06-30 $10,196,380 583,317
2022-06-30 $1,424,620 81,500
2022-03-31 $5,740,173 338,055
2022-03-31 $219,042 12,900
2021-12-31 $12,725,752 469,585
2021-09-30 $11,270,165 380,235

Report a Problem

Category
Description
Email (optional, for follow-up)